What were Samsung Biologics’ third-quarter revenue and operating profit?

Revenue reached 1.49 trillion won, an 18.5 percent increase from a year earlier. Operating profit was 640.1 billion won, up from 633.5 billion won in the same quarter last year.

What drove Samsung Biologics’ sales growth in the third quarter?

The company cited full-scale operations at four plants in Songdo, a production ramp-up at its fifth plant and sales from its first U.S.-based biomanufacturing facility in Rockville, Maryland, which it acquired in March.

Samsung Biologics Q3 net income down over 20%

Q: How much had Samsung Biologics secured in contract orders this year, and what sales growth does it now expect?

Cumulative contract orders for the year had reached $22 billion. Samsung Biologics raised its annual sales growth guidance to 20 percent from an earlier estimate of 15 to 20 percent, citing stable growth at its production plants.

Listen

Summary

Samsung Biologics reported third-quarter results on Wednesday, with net profit falling 21.2 percent year on year to 391.1 billion won. Revenue rose 18.5 percent to 1.49 trillion won, while operating profit edged up to 640.1 billion won. The company attributed sales growth to operations at its Songdo plants, increased production at its fifth plant and its Rockville facility. It raised its annual sales growth guidance to 20 percent.

Key Facts

The company’s third-quarter operating profit was 640.1 billion won, compared with 633.5 billion won a year earlier.
Samsung Biologics said cumulative contract orders for the year had reached $22 billion.
The company raised its annual sales growth guidance from an earlier estimate of 15 to 20 percent, citing stable growth at its production plants.
Samsung Biologics acquired its first U.S.-based biomanufacturing facility in Rockville, Maryland, in March.

By Yonhap

Published Oct 21, 2026 4:15 pm KST
Updated Oct 21, 2026 4:48 pm KST

Samsung Biologics' plant 4 in Incheon's Songdo / Courtesy of Samsung Biologics

Samsung Biologics, the biotech arm of Samsung Group, on Wednesday reported its third-quarter net profit of 391.1 billion won ($295.2 million), down 21.2 percent from a year earlier.

The contract development and manufacturing organization (CDMO) service provider, which offers comprehensive development and manufacturing solutions, said in a regulatory filing that it posted 640.1 billion won in operating profit for the quarter, compared with 633.5 billion won a year ago.

Revenue rose 18.5 percent to 1.49 trillion won.

The company attributed its sales increase to full-scale operations at four plants in Songdo, just west of Seoul, a ramp-up in production at its fifth plant, as well as sales generated from its first U.S.-based biomanufacturing facility in Rockville, Maryland, acquired in March.

The company said it will continue to expand its contract development and manufacturing (CDMO) business, with cumulative contract orders for this year reaching $22 billion.

It also raised the company's annual sales guidance this year to 20 percent, from the early estimate of 15 to 20 percent, citing stable growth of its production plants.

Explore More